Onconetix Inc (ONCO) FinancialsONCOFinancialOnconetix Inc

Evaluating the bottom line, Onconetix Inc maintains a gross margin of 25.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13112.09%, while the net margin is -16748.27%. These profitability ratios, combined with a Return on Equity (ROE) of -105.23%, provide a clear picture of how effectively ONCO converts its operational activities into shareholder value.

In the context of the broader market, ONCO competes directly with industry leaders such as OGEN and SHPH. With a market capitalization of $3.20M, it holds a significant position in the sector. When comparing efficiency, ONCO's gross margin of 25.13% stands against OGEN's N/A and SHPH's N/A. Such benchmarking helps identify whether Onconetix Inc is trading at a premium or discount relative to its financial performance.

Onconetix has shown erratic financial performance, with total revenues peaking at 711,976 in Q4 2024 but dropping to 17,120 in Q2 2026. The gross margin has fluctuated significantly, with a recent low of 25.13%.